Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®)
and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with
overactive bladder and age associated memory impairment.